IMUX · Immunic, Inc.

Immunic, Inc. has implemented a 1-for-10 reverse stock split of its common stock, effective at 12:01 AM Eastern Time on April 27, 2026. The Board of Directors approved the specific ratio following stockholder authorization at a special meeting held on April 14, 2026, which granted discretion to select a ratio within a 1-for-10 to 1-for-30 range. The Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation was filed with the Secretary of State of Delaware on April 22, 2026, to effect the split. Consequently, every ten shares of issued and outstanding common stock were combined into one share, reducing the total outstanding shares from approximately 136 million to approximately 13.6 million. The par value of $0.0001 per share and the number of authorized shares remain unchanged. The company explicitly stated that the reverse stock split is primarily intended to allow Immunic to meet its contractual obligations under a securities purchase agreement entered into with institutional and accredited investors on February 12, 2026. The common stock continues to trade on the Nasdaq Capital Market under the symbol 'IMUX' but has been assigned a new CUSIP number, 4525EP200. Proportionate adjustments will be made to outstanding stock options, restricted stock units, and warrants. Stockholders who would otherwise be entitled to fractional shares will receive cash payments in lieu thereof.